Maze Competitors
| MAZE Stock | 47.59 0.12 0.25% |
Maze Therapeutics vs Takeda Pharmaceutical Correlation
Very poor diversification
The correlation between Maze Therapeutics Common and TAK is 0.81 (i.e., Very poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Maze Therapeutics Common and TAK in the same portfolio, assuming nothing else is changed.
Moving together with Maze Stock
Moving against Maze Stock
| 0.74 | MSFT | Microsoft | PairCorr |
| 0.7 | HPQ | HP Inc | PairCorr |
| 0.38 | MMM | 3M Company | PairCorr |
| 0.36 | BRK-A | Berkshire Hathaway | PairCorr |
Maze Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Maze Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Maze and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Maze Therapeutics Common does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Maze Stock performing well and Maze Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Maze Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| COR | 1.11 | 0.04 | 0.00 | 0.16 | 2.25 | 2.01 | 11.54 | |||
| REGN | 1.52 | 0.30 | 0.16 | 0.74 | 1.34 | 3.40 | 8.86 | |||
| IDXX | 1.16 | (0.26) | 0.00 | (0.20) | 0.00 | 3.61 | 9.91 | |||
| HLN | 0.99 | 0.21 | 0.12 | 0.95 | 0.97 | 2.81 | 6.06 | |||
| CI | 1.23 | 0.11 | 0.06 | 0.26 | 1.16 | 3.20 | 7.49 | |||
| ELV | 1.65 | (0.05) | 0.00 | 0.05 | 2.97 | 3.78 | 19.95 | |||
| BDX | 1.05 | 0.15 | 0.14 | 0.24 | 0.75 | 2.93 | 7.14 | |||
| ELAN | 1.56 | 0.15 | 0.04 | 2.60 | 1.85 | 3.66 | 10.56 | |||
| ARGX | 1.20 | 0.01 | (0.05) | 0.02 | 1.68 | 2.29 | 7.34 | |||
| TAK | 0.86 | 0.38 | 0.41 | 1.55 | 0.00 | 2.49 | 4.49 |
Cross Equities Net Income Analysis
Compare Maze Therapeutics Common and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COR | (207.7 M) | 719 M | 433.7 M | 276.5 M | (134.9 M) | 1.4 B | 414.5 M | 1.7 B | 855.4 M | (3.4 B) | 1.5 B | 1.7 B | 1.7 B | 1.5 B | 1.6 B | 1.8 B | 1.9 B |
| REGN | (3.3 M) | (221.8 M) | 750.3 M | 424.4 M | 348.1 M | 636.1 M | 895.5 M | 1.2 B | 2.4 B | 2.1 B | 3.5 B | 8.1 B | 4.3 B | 4 B | 4.4 B | 4.5 B | 4.7 B |
| IDXX | 3.2 M | 161.8 M | 178.3 M | 187.8 M | 181.9 M | 192.1 M | 222 M | 263.1 M | 377 M | 427.7 M | 581.8 M | 744.8 M | 679.1 M | 845 M | 887.9 M | 1.1 B | 1.1 B |
| HLN | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 1.1 B | 1.4 B | 1.1 B | 1 B | 1.4 B | 1.7 B | 1.2 B |
| CI | (854.6 M) | 1.3 B | 1.6 B | 1.5 B | 2.1 B | 2.1 B | 1.9 B | 2.2 B | 2.6 B | 5.1 B | 8.5 B | 5.4 B | 6.7 B | 5.2 B | 3.4 B | 3.9 B | 4.1 B |
| ELV | 172.4 M | 2.6 B | 2.7 B | 2.7 B | 2.6 B | 2.6 B | 2.5 B | 3.8 B | 3.8 B | 4.8 B | 4.6 B | 6.1 B | 5.9 B | 6 B | 6 B | 5.7 B | 3.3 B |
| BDX | 88 M | 1.2 B | 1.3 B | 1.2 B | 695 M | 976 M | 1.1 B | 311 M | 1.2 B | 874 M | 2.1 B | 1.8 B | 1.5 B | 1.7 B | 1.7 B | 1.9 B | 2 B |
| ELAN | (210.8 M) | (210.8 M) | (210.8 M) | (210.8 M) | (210.8 M) | (210.8 M) | (47.9 M) | (310.7 M) | 86.5 M | 67.9 M | (560.1 M) | (483 M) | (78 M) | (1.2 B) | 338 M | 304.2 M | 319.4 M |
| ARGX | (4.5 M) | (4.5 M) | (12.8 M) | (8.5 M) | (12.5 M) | (16.7 M) | (22.5 M) | (33.7 M) | (76.2 M) | (181.2 M) | (608.5 M) | (407.6 M) | (709.6 M) | (295.1 M) | 833 M | 749.7 M | 787.2 M |
| TAK | 119.6 B | 124.2 B | 131.2 B | 106.7 B | (145.8 B) | 80.2 B | 114.9 B | 186.9 B | 109.1 B | 44.2 B | 376 B | 230.1 B | 317 B | 144.1 B | 107.9 B | 97.1 B | 155.3 B |
Maze Therapeutics Common and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Maze Therapeutics Common financial statement analysis. It represents the amount of money remaining after all of Maze Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Maze Therapeutics Competitive Analysis
The better you understand Maze Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Maze Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Maze Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Maze Therapeutics Competition Performance Charts
Five steps to successful analysis of Maze Therapeutics Competition
Maze Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Maze Therapeutics Common in relation to its competition. Maze Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Maze Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Maze Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Maze Therapeutics Common, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Maze Therapeutics position
In addition to having Maze Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Debt ETFs Thematic Idea Now
Broad Debt ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Debt ETFs theme has 302 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Debt ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Maze Therapeutics Correlation with its peers. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Will Pharmaceuticals sector continue expanding? Could Maze diversify its offerings? Factors like these will boost the valuation of Maze Therapeutics. Expected growth trajectory for Maze significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Maze Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Maze Therapeutics Common is measured differently than its book value, which is the value of Maze that is recorded on the company's balance sheet. Investors also form their own opinion of Maze Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Maze Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Maze Therapeutics' market value can be influenced by many factors that don't directly affect Maze Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Maze Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Maze Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Maze Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.